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Although Raf-1 is a critical Ras effector target, how
Rasmediates Raf-1 activation remains unresolved. Raf-1
residues 55–131 define a Ras-binding domain essential
for Raf-1 activation. Therefore, our identification of a
second Ras-binding site in the Raf-1 cysteine-rich do-
main (residues 139–184) was unexpected and suggested
a more complex role for Ras in Raf-1 activation. Both
Ras recognition domains preferentially associate with
Ras-GTP. Therefore, mutations that impair Ras activity
by perturbing regions that distinguish Ras-GDP from
Ras-GTP (switch I and II) may disrupt interactions with
either Raf-1-binding domain. We observed that muta-
tions of Ras that impaired Ras transformation by per-
turbing its switch I (T35A and E37G) or switch II (G60A
and Y64W) domain preferentially diminished binding to
Raf-1-(55–131) or the Raf-1 cysteine-rich domain, respec-
tively. Thus, these Ras-binding domains recognize dis-
tinct Ras-GTP determinants, and both may be essential
for Ras transforming activity. Finally, since Ha-Ras
T35A and E37G mutations prevent Ras interaction with
full-length Raf-1, we suggest that Raf-Cys is a cryptic
binding site that is unmasked upon Ras interaction with
Raf-1-(55–131).
Ras proteins are molecular switches controlled by GDP/GTP
cycling (1). These proteins are transiently activated in response
to ligand-stimulated receptor tyrosine kinases (2, 3). Upon
activation, Ras complexes with and promotes activation of the
Raf-1 serine/threonine kinase (4, 5). Raf-1 then activates mito-
gen-activated protein kinase (MAPK)1 kinases (MEKs), which
in turn phosphorylate and activate MAPKs. Activated MAPKs
translocate to the nucleus where they regulate the activities of
Elk-1 and other nuclear transcription factors (6).
Although substantial evidence supports the importance of
Ras-Raf-1 interactions for Ras-mediated signaling and trans-
formation, the precise role of Ras in activating Raf-1 remains
unresolved (7). The potent transforming activity of membrane-
targeted forms of Raf-1 suggests that Ras-mediated transloca-
tion of Raf-1 to the plasma membrane is an important step in
Raf-1 activation (8, 9). However, it is clear that Ras-Raf-1
interaction alone is not sufficient, and subsequent Ras-inde-
pendent events are required for full Raf-1 kinase activation.
For example, there is evidence that Raf-1 interaction with
14-3-3 proteins (10–14), lipids (15), and protein kinases (16–
19) contributes to full Raf-1 kinase activation. Whether Ras
simply promotes Raf-1 membrane association or also modu-
lates the subsequent activation events is presently unclear.
Yeast two-hybrid and in vitro binding studies demonstrated
that Raf-1 residues 55–131 are sufficient for stable association
with Ras (20–22). Additionally, recent structural studies con-
ducted with both Ras and the Ras-related protein, Rap1A,
indicate that Raf-1 residues 55–131 interact with residues
33–41 in the Ras effector region (23, 24). Finally, the critical
role for Raf residues 55–131 in Ras-mediated activation of
Raf-1 is demonstrated by the ability of a point mutation, Raf
(R89L), to disrupt Ras-Raf-1 binding and Raf-1 kinase activa-
tion (25). However, observations that mutations outside the
Ras effector domain impair Ras-Raf-1 binding and Ras-medi-
ated cell signaling (26–28) suggest that other Ras recognition
elements may contribute to Raf-1 kinase regulation.
We have recently characterized a second Ras-GTP-binding
site, located in the cysteine-rich domain of Raf-1 (residues
139–184), which interacts with Ras both in vitro and in vivo
(29). Additionally, peptides from this region blocked Ras-medi-
ated activation of MAPKs (30). The importance of a second
Ras-binding domain in Raf-1 is supported by a report that
mutations in the Raf-1 cysteine-rich region reduced Raf-1-Ras
binding by 55% and Raf-1 kinase activity by 60–90% (27).
Moreover, specific mutations in the cysteine-rich or kinase
domains of D-Raf reversed the loss of function of a D-Raf
variant containing a mutation analogous to c-Raf-1(R89L),
leading Perrimon and co-workers (31) to speculate that the
cysteine-rich domain formed negative regulatory contacts with
the kinase domain, which are relieved upon binding Ras. How-
ever, it is presently unclear if the Raf-1 cysteine-rich domain
recognizes Ras-GTP binding determinants distinct from those
that interact with Raf-1 residues 55–131 and if both Ras-Raf-1
interacting sites are required for Ras signaling and
transformation.
Both Ras recognition sites of Raf-1 preferentially bind Ras-
GTP. Therefore, mutations that impair Ras transforming ac-
tivity by causing disruptions in regions of Ras whose confor-
mation differs between Ras-GDP and Ras-GTP (switch I and II)
may disrupt interactions with either Ras-binding site of Raf-1.
To investigate the significance of the two Ras-binding sites in
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Raf-1 and to elucidate the regions of activated Ras-GTP impor-
tant for interactions with the Raf-1 cysteine-rich region, we
determined if mutations that abolished Ras transforming ac-
tivity also perturbed Ras interaction with the two distinct
Ras-interacting fragments of Raf-1. Our observations suggest
that the Raf-1 cysteine-rich domain contains a cryptic binding
site, which recognizes region(s) of Ras different from those that
bind Raf-1 residues 55–131, and both of these Ras-interacting
sites may be necessary for Ras-mediated transformation.
EXPERIMENTAL PROCEDURES
Generation of Ha-Ras Mutants and Expression Constructs—Genera-
tion of the mammalian expression constructs encoding Ha-Ras(G12V),
Ha-Ras(G12V, E37G), Ha-Ras(T35A), Ha-Ras(Q61L), Ha-Ras(G60A),
and Ha-Ras(Y64W) have been described elsewhere (26, 32–34). Mutant
Ha-ras (wild type or Q61L) sequences encoding T35W or I36W substi-
tutions were generated by oligonucleotide-directed mutagenesis using
the Mutator Kit (Stratagene, La Jolla, CA) and confirmed by dideoxy
sequencing method using Sequenase (U. S. Biochemical Corp.). The
mutant Ha-ras sequences were then introduced into the pAT-ras bac-
terial expression vector and into the pZIP-NeoSV(X)1 retrovirus vector
for expression in mammalian cells (36).
Expression and Purification of Ras and Raf-1 Proteins—Ha-ras se-
quences encoding Ha-Ras(G12V) and Ha-Ras(G12V, E37G) were intro-
duced into the pGEX bacterial expression vector, expressed as gluta-
thione S-transferase (GST) fusion proteins, and cleaved from GST using
thrombin (Sigma). The remaining Ha-Ras mutant proteins were ex-
pressed and purified as described previously (37). Complex formation
of Ras and GMPPCP, a non-hydrolyzable GTP analog (Boehringer
Mannheim), is described elsewhere (38). Raf-N (residues 2–140) and
Raf-Cys (residues 136–188) were provided by S. Ghosh (22, 29) and
were also prepared as GST-fusion proteins (15).
Cell Culture and Transformation Assays—NIH 3T3 cells were trans-
fected using previously described procedures (39), and the appearance
of transformed foci was quantitated after 14–16 days. Cell lines with
stable expression of each mutant Ha-Ras protein were established by
maintaining transfected cultures in growth medium supplemented with
G418 at 400 mg/ml (Geneticin, Life Technologies, Inc.). Tumorigenicity
was determined by subcutaneous inoculation of each cell line (1 3 105
cells/site) into athymic nude mice as described previously (39).
Direct Ras Binding Assay—Ras-GMPPCP was labeled with stoichi-
ometric amounts of [g-32P]GTP. Ras-GTP (0.2 nM) was incubated with
0.5 mM Raf-1-GST fusion fragments in 20 mM Hepes, pH 7.4, 1 mM
MgCl2, 1 mg/ml bovine serum albumin, and 0.3% Triton X-100 as
described elsewhere (40). The Ras-Raf-1 complex was isolated by bind-
ing the GST-fusion fragment to glutathione-coated agarose beads, and
the amount of radiolabeled Ras bound was determined by scintillation
counting. Assays were performed at least three times in duplicate with
GST background values subtracted from the amount of Ras-GTP
detected.
Enzyme-linked Immunosorbent Assay—An enzyme-linked immu-
nosorbent capture assay was employed as a second, distinct assay to
further assess the binding profiles of several non-transforming Ras
mutants and has been summarized elsewhere (29). Essentially, 100
pmol of Ras-GMPPCP was plated onto 96-well microtiter plates for 2 h
at room temperature. The ability of various Ha-Ras mutants to capture
100 pmol of Raf-GST fusion fragments and corresponding amounts of
GST in a buffer containing 10 mM Na2HPO4, pH 7.4, 0.5% gelatin,
0.05% Tween 20, and 0.2% sheep serum was measured by an anti-GST
antibody (Santa Cruz Biotechnology, Inc.) at a 1:2500 dilution.
RESULTS AND DISCUSSION
Oncogenic Ras Interaction with Raf-1 Residues 55–131 Alone
Is Not Sufficient for Ras Transforming Activity—Although we
recently demonstrated that the cysteine-rich domain of Raf-1
(residues 139–184) associates with Ras both in vitro and in vivo
(29), the role of this interaction in Ras transforming activity is
unclear. Given the preferential binding between active GTP-
bound Ras and fragments encoding both the cysteine-rich do-
main (Raf-1 residues 136–188, Raf-Cys) and Raf-1 residues
55–131 (Raf-1 residues 1–140, designated Raf-N) (22, 29), we
anticipated that Raf-N and Raf-Cys are likely to interact with
regions of Ras whose conformation is sensitive to its guanine
nucleotide-bound state. Two such regions of Ras identified to
undergo conformational changes between GTP- and GDP-
bound forms of Ras are commonly referred to as switch I
(residues 30–38 in loop 2/b strand 3) and switch II (residues
59–76 of loop 4 and helix 2) (41, 42). Thus, we evaluated the
consequences of mutations that impair oncogenic Ras trans-
forming activities via perturbations in switch I or II on Raf-N
and Raf-Cys binding. These analyses may elucidate the re-
gion(s) of Ras involved in binding Raf-Cys and establish a role
for this interaction in Ras transformation.
The biochemical and biological consequences of each muta-
tion to Ras are summarized in Table I. Like wild type Ras, two
different transforming mutants of Ras (G12V and Q61L) re-
tained high affinity binding to both Raf-N and Raf-Cys (Fig.
1A). Given the GTP dependence of Ras interactions with the
two Ras-Raf-1 interacting domains of Raf-1, taken together
with recent data showing that Raf-1 residues 55–131 bind
directly to the switch I domain of Ras (23, 24), we postulated
that Raf-Cys requires the switch II domain for its interaction
with Ras. Hence, to better characterize the regions of Ras
required for Raf-Cys binding, we determined whether a muta-
tion that disrupted switch II, but not switch I, altered Ras
binding to Raf-N or Raf-Cys.
For these studies, we used Ras G60A and Y64W switch II
mutants that abolish oncogenic Ras transforming activity (26,
43). Ras residue Gly-60 interacts with the g-phosphate of GTP,
and this interaction is believed to be crucial for propagating
conformational changes within the switch II domain of Ras.
Trypsin cleavage profiles and fluorescence analysis of muta-
tions analogous to the Ras G60A substitution in other GTP-
binding proteins (Gsa and EF-Tu) indicate that this mutation
disrupts switch II but not switch I (44–46). Moreover, fluores-
cence analysis using 8-anilino-1-naphthalenesulfonic acid dye
complexed with wild type and G60A Ras-GTP provides addi-
tional evidence that substitution of alanine for glycine at posi-
tion 60 alters the active conformation of Ha-Ras (26).
Although we detected an association between Raf-N and both
the Ras(G60A) and Ras(Y64W) variants, we did not observe
complex formation between these Ras mutants and Raf-Cys
(Fig. 1B). Thus, these results show that whereas Raf-N inter-
acts with switch I (23, 24), Raf-Cys requires an intact switch II
region for binding to Ras. This is consistent with a previous
observation that mutations in the switch II region of Ras (in-
cluding residue 64) perturb interactions between Ras and var-
ious putative effector proteins (47). Furthermore, the observa-
TABLE I
Consequences of switch I or II disruptions on Ras transforming






Noneb 1 2 1 1 1
G60A 2c II 1 1 2
Y64W 2c II NDd 1 2
T35A 2 I 2 2 1
E37G 2 I 2e 2 1
T35W 2 I and II ND 2 2
I36Wf 1 None ND 1 1
a Consequences of each mutation on oncogenic Ras(G12 or Q61L)
focus-forming activity in NIH 3T3 transformation assays; focus-forming
activity lost (2) or retained (1) is indicated.
b Oncogenic Ras(12V) or Ras(61L).
c Abolishes v-Ha-Ras transforming activity (26, 43).
d ND, not determined.
e Determined by yeast two-hybrid binding analysis (32).
f Introduction of I36W caused activation of wild type Ha-Ras trans-
forming potential, showed approximately 10% of the focus-forming ac-
tivity seen with Ha-Ras(Q61L) (3–4 3 103 transformed foci/mg of plas-
mid DNA), and caused tumor formation of mice inoculated with NIH
3T3 cells.2
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tion that the G60A and Y64W mutations abolish Ras
transforming activity without impairment of Raf-N binding
suggests that Ras interaction with Raf-N alone is not sufficient
for Ras biological activity.
The Ras Interaction Site in Raf-Cys Requires an Intact
Switch II Domain for Ras Binding and Is Cryptic in Raf-1—
Previous studies have shown that the T35A and E37G effector
domain mutations abolished Ras binding to full-length Raf-1
and impaired oncogenic Ras transforming activity (32, 48).
Consistent with the inability of these switch I mutants to bind
full-length Raf-1, we were unable to detect a stable complex
between T35A and E37G variants of Ras and Raf-N in vitro
(Fig. 1B). However, the ability to bind the isolated Raf-Cys
domain was retained (Fig. 1B). These results are also consist-
ent with earlier observations that Ras-Raf-N (residues 55–131)
binding contacts involve the Ras effector domain (23, 24) and
that these interactions are required for Ras-mediated activa-
tion of Raf-1 (25). Finally, we had previously observed that
mutations R256G, S257L, and S257P in the highly conserved
central region of Raf-1 (commonly referred to as the CR2 do-
main) or the removal of Raf-1 COOH-terminal residues 247–
648 are required to allow Ras(G12V, E37G) interaction with
Raf-1 (32), indicating that the Ras binding determinants in
Raf-Cys are masked in full-length Raf-1 (Fig. 2).
The inability of Raf-N to complex with the biologically inac-
tive T35A mutant may result from diminished interactions
between position 35, magnesium, GTP, and possibly the Asp-38
residue (48, 49). It is also not surprising that the E37G muta-
tion disrupted interactions with Raf-N, as the x-ray structure
of the binding interface between Raf-1 residues 55–131 and
Rap1A showed that the Glu-37 residue of Rap1A was in close
contact with this Raf-1 sequence and was involved in water-
mediated protein-protein interactions. Rap1A shares complete
identity with Ras residues 32–40 and can associate with most
Ras effectors, including Raf-1, RalGDS, and Ras GTPase-acti-
vating proteins (50–52).
Tryptophan Substitutions at Ras Residues 35 or 36 Cause
Opposing Biological Consequences—We also determined the
consequences of two adjacent Ras effector domain mutations,
T35W and I36W, on the properties of normal or oncogenic Ras
(Table I). We found that the Ras T35W mutant, but not I36W,
abolished the transforming activity of Ras(Q61L). Instead, the
I36W mutation alone was sufficient to activate wild type Ras
transforming potential. A similar gain of function mutation at
this position has been described previously (53). In contrast to
the minor perturbations observed in the switch I region of
Ras(I36W), NMR structural studies of the Ras(T35W) mutant
showed pronounced alterations in both switch I and switch II.2
Consistent with our suggestion that Ras interaction with both
Raf-N and Raf-Cys is important for Ras transformation, we
found that Ras(I36W) retained binding to both Raf-N and Raf-
Cys (Fig. 1A), whereas the nontransforming Ras(T35W) mu-
tant failed to interact with either Raf-1 sequence (Fig. 1B).
Our analyses of mutations that impair Ras transformation
as a consequence of perturbations to either the Ras switch I or
switch II domain suggest that Ras transforming activity re-
quires interaction with two distinct NH2-terminal Raf-1 se-
quences. Furthermore, Raf-N and Raf-Cys demonstrated op-
posing binding profiles with Ras proteins containing mutations
that disrupt switch I (T35A and E37G) versus switch II (G60A
and Y64W), indicating that they recognize distinct Ras GTP-
binding elements. These observations, together with our dem-
2 J. K. Drugan, R. Khosravi-Far, C. J. Der, and S. L. Campbell,
manuscript in preparation.
FIG. 1. Both Ras-binding domains of Raf-1 appear necessary
for Ras-mediated transformation. Two distinct Raf-1 fragments
were tested for their ability to bind various mutants of Ras as described
under “Experimental Procedures.” A, transforming Ras mutants bound
both Raf-N and Raf-Cys. B, Ras variants with switch I or II defects
lacked the ability to interact with at least one Ras recognition fragment.
FIG. 2. Ras(G12V, E37G) abolishes Ras interaction with Raf-N but not the isolated Raf-Cys domain. Yeast two-hybrid analysis was
done to determine the ability of Ras(G12V, E37G) to interact with different fragments of Raf-1 by procedures described previously (32). The
indicated Raf-1 residues were fused to transcriptional activating domains in the yeast reporter strain L40 as described below. A positive interaction
(1) was determined by growth on medium lacking histidine and by a positive indication of b-galactosidase activity using filter assays; (2) indicates
no interaction. At least four independent yeast colonies expressing the indicated pairs were tested. Raf-1 residues 51–131 were fused to the
VP-16-activating domain (a gift from A. Vojtek and J. Cooper) (20) while the remaining Raf-1 sequences were fused to the GAD-activating domain.
The Raf-1 CR2 mutants (R256G, S257L, S257P) were isolated and characterized previously (32). WT, wild type.
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onstration that peptides containing a consensus Ras binding
sequence from Raf-Cys can block Ras activation of MAPKs (30),
provide strong evidence that Ras interaction with Raf-Cys is a
critical step in Ras-mediated activation of Raf-1.
Previous studies determined that Raf-N represents a mini-
mal Ras binding sequence and that a mutation in this Raf-1
domain (R89L) prevented Ras interaction and activation of
full-length Raf-1 (25). Therefore, we speculated that the Ras-
binding elements in Raf-Cys are cryptic in the intact unstimu-
lated Raf-1 protein (29). In support of this hypothesis, we have
shown in the present study that two Ras effector domain mu-
tations (T35A and E37G), which impair Ras binding to both
full-length Raf-1 and Raf-N, did not abolish Ras binding to the
isolated Raf-Cys domain.
Recent observations that addition of the Ras membrane-
targeting sequence onto Raf-1 caused activation of Raf-1 trans-
forming activity suggested that Ras binding to Raf-N was im-
portant for Ras-mediated translocation of Raf-1 from the
cytosol to the plasma membrane (8, 9). Once at the membrane,
Ras-independent events have been proposed to trigger Raf-1
kinase activation. However, our observation that the G60A and
Y64W mutations retained interaction with Raf-N yet abolished
oncogenic Ras transforming activity suggests that Ras interac-
tion with Raf-Cys is also required for Raf-1 activation. There-
fore, Ras interaction with both Raf-N and Raf-Cys may be
necessary to promote Raf-1 association with the plasma mem-
brane. However, several lines of evidence suggest that the
NH2-terminal half of Raf-1 serves to negatively regulate the
activity of the COOH-terminal kinase domain because muta-
tion, insertion, or deletion of these regions results in oncogenic
activation of the Raf-1 kinase (54–56). Therefore, Ras binding
to Raf-Cys may relieve the negative regulatory action of the
Raf-1 NH2 terminus to allow other events to activate Raf-1.
This hypothesis is consistent with our observation that the
Ras-binding site in Raf-Cys is cryptic in full-length Raf-1. Ad-
ditionally, it provides an explanation for previous findings that
specific mutations in the cysteine-rich and kinase domains of
D-Raf reverse the loss of function associated with a D-Raf
mutation in the Raf-N site that abolishes Ras binding.
In light of our observations, we propose a model for the role
of Ras-mediated activation of Raf-1 via two distinct Ras bind-
ing sequences in Raf-1 (Fig. 3). Binding of the Ras-GTP switch
I domain to Raf-N promotes both membrane localization of
Raf-1 and exposes residues in Raf-Cys for binding Ras-GTP and
possibly other membrane components. Interactions with Raf-
Cys then trigger loss of the negative regulatory activity of the
Raf-1 NH2 terminus to allow subsequent Ras-independent
events to promote Raf-1 kinase activation.
The Raf-Cys zinc finger motif also contains binding determi-
nants for phosphatidylserine (15) and 14-3-3 proteins (7).
Hence, Ras interaction with Raf-Cys may modulate their ac-
tivities to mediate Raf-1 activation. By analogy with the cys-
teine-rich domain of protein kinase C (35, 57–59), the Ras-
binding site in Raf-Cys may functionally substitute for
diacylglycerol, and synergistic binding of Ras and phosphati-
dylserine may be involved in release of negative regulatory
constraints between the NH2 and COOH termini of Raf-1. It is
also possible that exposure of the Ras-binding elements in
Raf-Cys may require release of 14-3-3 proteins (14). In sum-
mary, the Ras-Raf-Cys interaction may induce the removal of
negative regulatory action in the Raf-1 NH2 terminus and
consequently facilitate Raf-1 activation by additional events
such as phosphorylation of select residues in Raf-1.
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